Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
In an unexpected twist, the advisory committee that convened today on the experimental Alzheimer’s treatment aducanumab overwhelmingly said that drugmaker Biogen has failed to…
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
The latest news about Biogen’s controversial Alzheimer’s drug popped into my email at 8:26 a.m. last Wednesday. Coincidentally it arrived just as I was…
In another step toward what could be the first treatment for early stage Alzheimer’s, Biogen and Eisai today said they have completed an application…
Hours feel like days. Days feel like months. And months? Well they can feel like a decade. Particularly when you are awaiting the restart…
Being Patient Senior Reporter Phil Gutis spent the day with our patient advisor, Jeff Borghoff, who was the first recipient in Biogen’s latest trial…